Richard G. Harris, MD, presented “The Present and Future of LUGPA” during the 30th Annual International Prostate Cancer Update on January 23rd, 2020 in Beaver Creek, Colorado.
How to cite: Harris, Richard G. “The Present and Future of LUGPA” January 23rd, 2020. Accessed Nov 2024. https://dev.grandroundsinurology.com/advanced-prostate-cancer-whats-changing/
The Present and Future of LUGPA – Summary:
Richard G. Harris, MD, CEO of UroPartners and President of LUGPA, discusses the Large Urology Group Practice Association’s (LUGPA) 2020 Strategic Plan. He observes that as the United States’ population ages and grows, and as new technology causes the cost of treatment to rise, demands on urology practices will increase. LUGPA will help urologists meet these challenges by continuing its advocacy work protecting independent urology practice, especially in Washington, D.C., and by developing the leadership skills of young urologists through programs like LUGPA Forward and the Rising Chief Resident Summit. Other initiatives will focus on easing operational challenges, increasing member engagement, and ensuring organizational excellence.
In case you missed it, make sure to see Dr. Harris’s interview on the effects of COVID-19 on large urology practices, part of our collection of COVID-19 resources for urologists.
About The 30th Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. Dr. Harris delivered this educational activity during the 30th iteration of the meeting in January 2020.
For further educational activities from this conference, visit our collection page.
ABOUT THE AUTHOR
Richard Harris, MD, is a board-certified urologist with expertise in the treatment of advanced prostate cancer and health policy. He obtained his BA cum laude from Washington University in St. Louis, Missouri. He then completed a year of graduate work in biological science at the University of Illinois in Chicago, followed by medical school at the Chicago Medical School at Rosalind Franklin University. He completed residency training in general surgery and urology at Loyola University Medical Center in Chicago. Dr. Harris has been involved in clinical drug development and research on over 70 drug trials and has also been on the advisory board for several pharmaceutical companies. Currently, he sits on the Board of Directors of LUGPA and is LUGPA’s President. He is a founding member, CEO, and President of UroPartners, LLC, the largest group of urologists in the Midwest.
Dr. Harris is an Assistant Clinical Professor of Urology at the Loyola University Medical Center. His area of interest is urology and his specialty is advanced prostate cancer. Dr. Harris is also interested in BPH, sexual dysfunction, and kidney stone disease. Dr. Harris is one of the few urologists skilled in cryotherapy for prostate cancer.
